<b>OBJECTIVE</b>
<p>To
elucidate the pathogenesis of post-pancreatectomy diabetes (PPDM).</p>
<p><b>RESEARCH
DESIGN AND METHODS</b></p>
<p>Forty-eight
patients without diabetes undergoing either pancreatoduodenectomy (PD) (n = 20)
or distal pancreatectomy (DP) (n = 28) were included. 75-g oral glucose
tolerance test was performed every 6 months. Microbiome composition and
short-chain fatty acids in feces were examined before and 6 months after
surgery. The association of histological characteristics of the resected
pancreas with PPDM were examined.</p>
<p><b>RESULTS</b></p>
<p>During
follow-up (median, 3.19 years), 2 out of 20 PD patients and 16 out of 28 DP
patients developed PPDM. Proteobacteria relative abundance, plasma GLP-1, and
fecal butyrate levels increased only after PD. Postsurgical butyrate levels
were correlated with postsurgical GLP-1 levels. With no significant difference
in the volume of the resected pancreas between the surgical procedures, both
β-cell and α-cell areas in the resected pancreas were significantly higher in
DP patients than in PD patients. In DP patients, the progressors to diabetes
showed pre-existing insulin resistance compared with non-progressors, and both
increased α- and β-cell areas were predictors of PPDM. Furthermore, in DP
patients, α-cell and β-cell areas were associated with ALDH1A3 expression in
islets.</p>
<p><b>CONCLUSIONS</b></p>
We postulate that a
greater removal of β-cells contributes to the development of PPDM after DP.
Islet expansion along with pre-existing insulin resistance is associated with
high cellular-plasticity, which may predict the development of PPDM after DP.
In contrast, PD is associated with alterations of gut microbiome and increases
in SCFA production and GLP-1 secretion, possibly protecting against PPDM
development.
Funding
This work was funded by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (15K-19507), the Japan Foundation for Applied Enzymology, Takeda Science Foundation, and AstraZeneca. The study funders had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, or preparation.